New Company Joins With RPR To Develop Intrabody Technology

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new company formed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute, has joined the Rhône-Poulenc Rorer Gencell network to help accelerate the development of its innovate intrabody, or intracellular antibody, technology.

COLLEGEVILLE, Penn--Intra-immune Therapies, Inc., a new companyformed by Dr. Wayne Marasco, of the Dana-Farber Cancer Institute,has joined the Rhône-Poulenc Rorer Gencell network to helpaccelerate the development of its innovate intrabody, or intracellularantibody, technology.

An intrabody is an engineered human antibody that works insidea cell, offering the potential for blocking molecular changesthat can lead to dis-eases such as cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
6371178759112
Focused, high-dose radiotherapy doses may prolong survival and the interval to subsequent therapy for patients with advanced prostate cancer.
Data show increasing use of proton therapy overall but widening gaps in populations who have access to this treatment, says Curtiland Deville Jr., MD.
Related Content